Severe skin rash – now what? Mogamulizumab (MOG) is a humanized anti-CCR4 monoclonal antibody that is highly cytotoxic for adult T-cell leukemia/lymphoma (ATL) cells. A study found that some patients with CCR4-positive aggressive ATL who had received MOG treatment showed immense cutaneous adverse reactions. Especially after 2 cycles of treatment, they were most likely to develop the skin rash. However, the drugs undoubtedly are of first choice and effective. How are physicians supposed to handle the challenge? Read More
| Shopping Overview | ||||
| Type | Qtty | Discount | VAT | Price |
| Your basket is empty | ||||
| View Cart | ||||
